Literature DB >> 7044386

Clinical responses during gold therapy for rheumatoid arthritis. Changes in synovitis, radiologically detectable erosive lesions, serum proteins, and serologic abnormalities.

J T Sharp, M D Lidsky, J Duffy.   

Abstract

Gold therapy given to 73 patients with rheumatoid arthritis was associated with remission of synovitis for 3 months or longer in 27 patients and 50% or greater improvement in 20 patients. New joint deformities did not develop in patients who experienced remission, and progression of radiologically detectable erosive changes was prevented. Serum protein and serologic abnormalities were improved in all groups, but patients who had a good response experienced the greatest improvement. No single clinical or laboratory feature in the pretreatment assessment predicted response, but, as a group, the patients with the best response also ranked best for most prognostic indicators.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7044386     DOI: 10.1002/art.1780250508

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  23 in total

1.  Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate.

Authors:  O Sander; G Herborn; E Bock; R Rau
Journal:  Ann Rheum Dis       Date:  1999-05       Impact factor: 19.103

2.  Can treatment with methotrexate influence the radiological progression of rheumatoid arthritis?

Authors:  A A Drosos; A H Karantanas; D Psychos; C Tsampoulas; H M Moutsopoulos
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

3.  Cultured human cells can acquire resistance to the antiproliferative effect of sodium aurothiomalate.

Authors:  A Glennås; H E Rugstad
Journal:  Ann Rheum Dis       Date:  1986-05       Impact factor: 19.103

4.  Radiological evaluation of erosions: a quantitative method for assessing long-term remittive therapy in rheumatoid arthritis.

Authors:  W M O'Brien
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 5.  Joint damage in rheumatoid arthritis: radiological assessments and the effects of anti-rheumatic drugs.

Authors:  D L Scott; P A Bacon
Journal:  Rheumatol Int       Date:  1985       Impact factor: 2.631

Review 6.  What happens to patients with rheumatoid arthritis? The long-term outcome of treatment.

Authors:  T D Spector; D L Scott
Journal:  Clin Rheumatol       Date:  1988-09       Impact factor: 2.980

7.  Does second-line therapy affect the radiological progression of rheumatoid arthritis?

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Ann Rheum Dis       Date:  1984-02       Impact factor: 19.103

8.  Prediction of progressive joint damage in patients with rheumatoid arthritis receiving gold or D-penicillamine therapy.

Authors:  P T Dawes; P D Fowler; R Jackson; M Collins; M F Shadforth; R Stone; D L Scott
Journal:  Ann Rheum Dis       Date:  1986-11       Impact factor: 19.103

9.  Radiological progression in rheumatoid arthritis: how many patients are required in a treatment trial to test disease modification?

Authors:  J T Sharp; F Wolfe; M Corbett; H Isomaki; D M Mitchell; D E Furst; J Sibley; M Shipley
Journal:  Ann Rheum Dis       Date:  1993-05       Impact factor: 19.103

10.  Progressive joint damage during penicillamine therapy for rheumatoid arthritis.

Authors:  D L Scott; A Greenwood; R Bryans; E C Huskisson
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.